This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Wins Last Week: 5 Best ETFs
by Sweta Killa
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
Zacks Investment Ideas feature highlights: Pfizer, Caterpillar, and Johnson & Johnson
by Zacks Equity Research
Pfizer, Caterpillar, and Johnson & Johnson are part of Zacks Investment Ideas article.
3 Blue-Chip Stocks With Rock-Solid Dividends
by Derek Lewis
Blue-chip stocks are companies that have consistently provided quality, reliability, and the ability to operate profitably in the face of both good and bad times.
Top Analyst Reports for Pfizer, Progressive & PNC
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Progressive Corporation (PGR), and The PNC Financial Services Group, Inc. (PNC).
Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
by Zacks Equity Research
Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca
by Zacks Equity Research
GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.
Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed
by Kinjel Shah
GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results
GDP Growth Rate Contracts for Two Straight Quarters
by Zacks Equity Research
GDP Growth Rate Contracts for Two Straight Quarters.
Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.
Q2 GDP -0.9%, So We're in a Recession... Right?
by Mark Vickery
It's a back-of-the-envelope calculation, this notion that two negative-growth quarters in a row constitutes a recession, but analysts are hesitating in real time to paste the "big R" onto our current economic condition.
Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 16.57% and 5.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is iShares MSCI USA Value Factor ETF (VLUE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VLUE
Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.
Is First Trust Rising Dividend Achievers ETF (RDVY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RDVY
Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.
Markets Wait For Fed FOMC, Big Tech Earnings and Economic Data
by Zacks Equity Research
Markets Wait For Fed FOMC, Big Tech Earnings and Economic Data.
Big Week for Q2 Earnings, Economic Data
by Mark Vickery
This will be the biggest week for stock market data -- economic prints and Q2 earnings -- so far.
Pfizer Q2 Preview: Quarterly Estimates Display Robust Growth
by Derek Lewis
The Zacks - Medical Sector has held up relatively well year-to-date, decreasing approximately 12% in value vs. the S&P 500's decline of 15%.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Markets Look to Finish Another Up-Week; AMX, TWTR in Different Q2 Directions
by Mark Vickery
Its the Dow that currently trades in the green this morning, partially on strong Q2 results from American Express (AXP).